NOVEL KINASE INHIBITORS AFURESERTIB AND PIM447 ARE ACTIVE ALONE AND IN COMBINATION WITH STANDARD THERAPIES, RESPECTIVELY, IN A PREDICTIVE MM IN VIVO MODEL, AND A CRISPR GENOME-WIDE SCREENING APPROACH IDENTIFIES CLINICALLY-RELEVANT BIOMARKERS DETERMINING SUSCEPTIBILITY TO THESE THERAPEUTIC STRATEGIES

Michael O'Dwyer

NOVEL KINASE INHIBITORS AFURESERTIB AND PIM447 ARE ACTIVE ALONE AND IN COMBINATION WITH STANDARD THERAPIES, RESPECTIVELY, IN A PREDICTIVE MM IN VIVO MODEL, AND A CRISPR GENOME-WIDE SCREENING APPROACH IDENTIFIES CLINICALLY-RELEVANT BIOMARKERS DETERMINING SUSCEPTIBILITY TO THESE THERAPEUTIC STRATEGIES

Medicine

Research output: Other contribution (Published) › Other contribution

Original language	English (Ireland)
Media of output	Other Item
Volume	103
Publication status	Published - 1 Apr 2018

Cite this

@misc{856d099f48ae4f6eaaecceac7a71a914,

title = "NOVEL KINASE INHIBITORS AFURESERTIB AND PIM447 ARE ACTIVE ALONE AND IN COMBINATION WITH STANDARD THERAPIES, RESPECTIVELY, IN A PREDICTIVE MM IN VIVO MODEL, AND A CRISPR GENOME-WIDE SCREENING APPROACH IDENTIFIES CLINICALLY-RELEVANT BIOMARKERS DETERMINING SUSCEPTIBILITY TO THESE THERAPEUTIC STRATEGIES",

author = "Michael O'Dwyer",

year = "2018",

month = apr,

day = "1",

language = "English (Ireland)",

volume = "103",

type = "Other",

}

NOVEL KINASE INHIBITORS AFURESERTIB AND PIM447 ARE ACTIVE ALONE AND IN COMBINATION WITH STANDARD THERAPIES, RESPECTIVELY, IN A PREDICTIVE MM IN VIVO MODEL, AND A CRISPR GENOME-WIDE SCREENING APPROACH IDENTIFIES CLINICALLY-RELEVANT BIOMARKERS DETERMINING SUSCEPTIBILITY TO THESE THERAPEUTIC STRATEGIES. / O'Dwyer, Michael.
2018.

Research output: Other contribution (Published) › Other contribution

TY - GEN

T1 - NOVEL KINASE INHIBITORS AFURESERTIB AND PIM447 ARE ACTIVE ALONE AND IN COMBINATION WITH STANDARD THERAPIES, RESPECTIVELY, IN A PREDICTIVE MM IN VIVO MODEL, AND A CRISPR GENOME-WIDE SCREENING APPROACH IDENTIFIES CLINICALLY-RELEVANT BIOMARKERS DETERMINING SUSCEPTIBILITY TO THESE THERAPEUTIC STRATEGIES

AU - O'Dwyer, Michael

PY - 2018/4/1

Y1 - 2018/4/1

M3 - Other contribution

VL - 103

ER -